The role of consolidation treatment in locally advanced unresectable nsclc

Current Oncology Reports

Volumn 15, Issue 4, 2013, Pages 424-432

  Fakhrejahani, Farhad ^a   Hashemi Sadraei, Nooshin ^b   Mekhail, Tarek ^c  

^a ST ELIZABETH HEALTH CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

Author keywords

Consolidation chemotherapy; Non small cell lung cancer; Stage III

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHASIA; ESOPHAGITIS; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TOXICITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RADIOSENSITIZATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CONSOLIDATION CHEMOTHERAPY; DRUG SUBSTITUTION; HUMANS; LUNG NEOPLASMS; NEOPLASM, RESIDUAL; RADIATION-SENSITIZING AGENTS;

EID: 84880776955     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0330-8     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-9.
3. Edelman MJ, Gandara DR, Roach 3rd M, Benfield JR. Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg. 1996;61:1564-72. (Pubitemid 26151395)
4. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181-90.
5. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-9. (Pubitemid 29415225)
6. Curran Jr WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452-60.
7. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910-7.
8. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-53. (Pubitemid 41095099)
9. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210-5. (Pubitemid 26302034)
10. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys. 1991;20:1183-90.
11. Albain KS, Crowley JJ, Turrisi 3rd AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002;20:3454-60.
12. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003;21:2004-10. (Pubitemid 46606390)
13. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer. 1998;34:838-44. (Pubitemid 28248494)
14. Scagliotti GV, Szczesna A, Ramlau R, et al. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer. 2006;94:1375-82. (Pubitemid 43772269)
15. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008;26:5755-60.
16. Gaspar L, Kelly K, Chansky K. Incidence of pneumonitis on SWOG 0023: preliminary analysis of radiation lung volumes and pneumonitis in an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib versus placebo maintenance in patients with inoperable stage III NSCLC. Lung Cancer. 2005;49 Suppl 2:S49.
17. Bastos BR, Hatoum GF, Walker GR, et al. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2010;5:533-9.
18. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer. 1998;82:842-50. (Pubitemid 28104162)
19. Horinouchi H, Sekine I, Sumi M, et al. Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer. Cancer Sci. 2013;104:93-7.
20. Gadgeel SM, Ruckdeschel JC, Patel BB, et al. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol. 2011;6:927-33.
21. Davies AM, Chansky K, Lau DH, et al. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006;24:5242-6. (Pubitemid 46631368)
22. Kawaguchi T, Takada M, Ando M, et al. A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer. Eur J Cancer. 2012;48:672-7.
23. Sekine I, Noda K, Oshita F, et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci. 2004;95:691-5. (Pubitemid 39255819)
24. Jain AK, Hughes RS, Sandler AB, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4:722-7.
25. Sakai H, Yoneda S, Kobayashi K, et al. Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer. 2004;43:195-201. (Pubitemid 38114748)
26. Garrido P, Rosell R, Massuti B, et al. Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clin Lung Cancer. 2009;10:180-6.
27. Garrido P, Massutí T, Morán T, Cardenal F, Juan O, Dómine M, et al. Concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel (D) and gemcitabine (G) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Results of the randomized SLCG 0008 phase II trial. J Clin Oncol. 2007;25(18S):7620.
28. Senan S, Cardenal F, Vansteenkiste J, et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol. 2011;22:553-8.
29. Xu Y, Ma S, Ji Y, et al. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Lung Cancer. 2011;72:327-32.
30. Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009;10:193-8.
31. Berghmans T, Van Houtte P, Paesmans M, et al. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer. 2009;64:187-93.
32. Huber RM, Engel-Riedel W, Kollmeier J, Andreas S, Staar S, Klautke G, et al. GILT study: oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): final results of a phase (ph) III study. J Clin Oncol. 2012;30(15 Suppl):7001.
33. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883-91.
34. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50. (Pubitemid 44917502)
35. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32. (Pubitemid 41058344)
36. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26:2450-6.
37. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-37. (Pubitemid 41540110)
38. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 2004;22:785-94. (Pubitemid 41103589)
39. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 2004;22:777-84. (Pubitemid 41103588)
40. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-9.
41. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-52. (Pubitemid 46733081)
42. Socinski MA, Stinchcombe TE, Moore DT, et al. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012;30:3953-9.
43. Marks LB, Garst J, Socinski MA, et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol. 2004;22:4329-40. (Pubitemid 41185153)
44. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348-56. (Pubitemid 35286797)
45. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004;22:4341-50. (Pubitemid 41185154)
46. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer. 2001;92:1213-23.
47. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I trial. Cancer. 2000;89:534-42. (Pubitemid 30640100)
48. Stinchcombe TE, Lee CB, Moore DT, et al. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. J Thorac Oncol. 2008;3:1279-85.
49. Stinchcombe TE, Morris DE, Lee CB, et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol. 2008;3:250-7. (Pubitemid 351654324)
50. Yamamoto S, Tsujino K, Ando M, Kawaguchi T, Kubo A, Isa S, et al. Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature. J Clin Oncol. 2012;30(15 Suppl):7000.